biote

biote

biote traces its roots to 2012, when it was founded to commercialize bioidentical hormone replacement therapy (BHRT) through standardized pellet-based treatments. The company went public in 2022 via a merger with Haymaker Acquisition Corp. III, a SPAC that valued the combined entity at roughly $700 million. Under CEO Terry Weber, biote operates both a medical practice network and a direct-to-consumer diagnostic business that ships at-home test kits for hormone levels. biote's revenue model is built on recurring practitioner purchases of hormone pellets and related supplies, booking $186 million in revenue for fiscal year 2023. The company does not operate clinics itself; it trains and supplies independent medical providers — predominantly in family medicine, obstetrics and gynecology, and wellness — who then administer treatments in-office. In December 2023, biote expanded its consumer reach by launching a telehealth platform that connects patients directly with affiliated practitioners following the purchase of an at-home lab test kit. The company is headquartered in Irving, Texas, with a centralized laboratory facility that handles proprietary pellet compounding and diagnostic processing. biote exited 2023 with 965 active clinic locations and disclosed a long-term target of reaching 6,000 total locations, though quarterly growth has been uneven. The firm added 567 new providers in 2023 while churning through some existing accounts — a dynamic that reflects the challenges of medical training adoption rather than capital-allocation strategy. biote is structurally distinct from a traditional family office or investment firm: it is an operating company with its own balance sheet, R&D pipeline, and a compliance footprint governed by FDA pharmacy compounding rules and CLIA lab certification. The company's expansion rests on a licensing model — practitioners pay for training and commit to purchasing supplies exclusively from biote — which creates both high-margin recurring revenue and regulatory concentration risk if the FDA shifts its enforcement posture on compounded hormones.